MOESM3 of Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Ratner, Paul; Andrews, Charles; Hampel, Frank; Martin, Bruce; Mohar, Dale; Bourrelly, Denis; Danaietash, Parisa; Mangialaio, Sara; Dingemanse, Jasper; Hmissi, Abdel; Bavel, Jay

doi:10.6084/m9.figshare.c.3734251_D3.v1

13223_2017_183_MOESM3_ESM.docx (23.3 kB)

MOESM3 of Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

journal contribution

posted on 2017-04-04, 05:00 authored by Paul Ratner, Charles Andrews, Frank Hampel, Bruce Martin, Dale Mohar, Denis Bourrelly, Parisa Danaietash, Sara Mangialaio, Jasper Dingemanse, Abdel Hmissi, Jay Bavel

Additional file 3: Table S1. Setipiprant trough plasma concentrations across dose groups at the end* of weeks 1 and 2 during Phase 2 and Phase 3 trials.

Funding

Actelion Pharmaceuticals

History

Usage metrics

Keywords

Allergy Rhinitis Efficacy Safety Mountain Cedar pollen Setipiprant

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM3 of Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Funding

Actelion Pharmaceuticals

History

Usage metrics

Categories

Keywords

Licence

Exports